October 9, 2013

Mitsubishi Electric to install proton therapy system in Okayama, Japan

TOKYO, 1 October 2013 – Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has signed an agreement to provide its innovative proton beam therapy system for cancer treatment to Tsuyama Chuo Hospital located in Okayama (a part of Tsuyama Jifu Group, Yoshinori Ukita, President). This will be the first particle therapy system in the Chugoku-Shikoku region, significantly expanding access to patients in southern Japan. The system will be part of a new treatment center expected to open in March 2016 that will be jointly operated with Okayama University.

Proton Beam Therapy System
The proton system features the new Universal Nozzle with high dose-rate capability. Testing is being performed at the in-house proton beam facility at Mitsubishi Electric’s Kobe factory to obtain Government approval in a timely manner. Mitsubishi Electric also provides staff training and commissioning support to facilitate the early start up of treatment.

New Treatment Center
Okayama University / Tsuyama Chuo Hospital Proton Beam Cancer Center, is located on the campus of Tsuyama Chuo Hospital (Shigeatsu Fujiki, Chairman), and will be operated jointly with Okayama University (Kiyoshi Morita, President). Tsuyama Chuo Hospital and Okayama University Medical School, Department of Radiation Oncology (Susumu Kanazawa, Professor and Department Chairman) will assume central roles in proton beam therapy, clinical research and education at the new facility. To date, Mitsubishi Electric has installed systems at eight of the 11 particle therapy facilities in Japan, and more than 16,000 patients have been treated at these facilities. Tsuyama Chuo Hospital will be the ninth facility to install a Mitsubishi Electric particle therapy system. Mitsubishi Electric will continue to provide and develop advanced particle therapy systems for use worldwide, and is committed to providing superb operational and maintenance support.


©

October 4, 2013

AVO wins 73% of all orders for proton technology

PeterHouse Corporate Finance reports AVO has won nearly three quarters of all new orders for proton beam installations worldwide in the past six months, with eight of the 11 new installations and 24 of the 33 new treatment rooms. It predicts AVO’s already big pipeline of orders will continue to grow, with Letters of Intent to date covering eight installations at about £26m for each installation.

Advanced Oncotherapy Plc (AVO) has announced Letters Of Intent (LOI) from 4 major organisations which require 8 of its LIGHT machines to be installed in initia sites in both the UK and US . This is very good news but what is really stunning is that these orders represent nearly three quarters of all the orders worldwide for Proton Beam Therapy machines placed in the last 6 months. Now MEDraysinte expects the world market for Proton Beam Therapy installations to triple over the next 5 years to 2018 and reach $2.5bn by 2030. We estimate that these orders are worth about £200m in total as the machines are installed over the next three years. As a result of this development, the risk with AVO has now shifted from development to delivery. If this dominant world market share is sustained in this rapidly growing market, then the present £10m valuation looks inappropriately low.




Related Files: 2013_10_02 AVO Analyst Note PH FINAL
©